Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone 32 mg Sustained Release (SR)/Bupropion 360 mg Sustained Release (SR) and Placebo in Obese Subjects With Type 2 Diabetes Mellitus

Trial Profile

A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone 32 mg Sustained Release (SR)/Bupropion 360 mg Sustained Release (SR) and Placebo in Obese Subjects With Type 2 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naltrexone/bupropion (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms COR-Diabetes
  • Sponsors Orexigen Therapeutics [CEASED]
  • Most Recent Events

    • 04 Sep 2020 Results of post hoc analysis of data from the 6 naltrexone ER/bupropion ER trials assessing the percent of subjects achieving a weight loss of 5% to 10%, 10% to 15%, and more than 15% at weeks 16, 52, 104, and 208 presented at the 2020 European and International Congress on Obesity
    • 26 Mar 2018 Based on the data from COR-I, COR-II, COR-BMOD, and COR-Diabetes trials, the Health Canada has approved CONTRAVE extended-release tablets for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults, as reported in a Valeant Canada media release.
    • 25 Apr 2017 According to an Orexigen Therapeutics media release, Health Canada has completed its screening phase and accepted for review a New Drug Submission for marketing approval of Contrave (naltrexone HCl and bupropion HCl). The regulatory submission was filed by Valeant Canada, an affiliate of Valeant Pharmaceuticals International, Inc.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top